Biological markers in the peritoneal dialysate effluent: Are they useful

Contributions to Nephrology

Volumn 163, Issue , 2009, Pages 54-59

  Krediet, Raymond T ^a,c   Sampimon, Denise E ^a   Vlijm, Anniek ^a   Coester, Annemieke M ^a   Struijk, Dirk G ^a   Smit, Watske ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Dianet Foundation Utrecht   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; DIALYSIS FLUID; INTERLEUKIN 6; VASCULOTROPIN A;

ARTICLE; HUMAN; METABOLISM; PATHOLOGY; PERITONEAL DIALYSIS; PERITONEUM; SCLEROSIS;

BIOLOGICAL MARKERS; CA-125 ANTIGEN; DIALYSIS SOLUTIONS; HUMANS; INTERLEUKIN-6; PERITONEAL DIALYSIS; PERITONEUM; SCLEROSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67651208704     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000223780     Document Type: Article

References (24)

1. Lasrich M, Maher JM, Hirszel P, Maher JF: Correlation of peritoneal transport rates with molecular weight: a method for predicting clearances. ASAIO J 1079;2:107-113.
2. Zemel D, Imholz ALT, de Waart DR, Dinkla C, Struijk DG, Krediet RT: Appearance of tumor necrosis factor α and soluble TNF-receptors I and II in peritoneal effluent of CAPD. Kidney Int 1994;46:1422-1430.
3. Imholz ALT, Koomen GCM, Struijk DG, Arisz L, Krediet RT: Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. Kidney Int 1993;43:1339-1346.
4. Douma CE, de Waart DR, Struijk DG, Krediet RT: Are phospholipase A2 and nitric oxide involved in the alterations in peritoneal transport during CAPD peritonitis? J Lab Clin Med 1998;132:329-340.
5. Vlijm A, de Waart DR, Zweers MM, Krediet RT: Effluent hydroxyproline in experimental peritoneal dialysis. Perit Dial Int 2007;27:210-213.
6. Reddingius RE, Schröder CH, Daha MR, Willems JL, Koster AM, Monnens LAH: Complement in serum and dialysate in children on continuous ambulatory peritoneal dialysis. Perit Dial Int 1995;15:49-53.
7. Krediet RT, Asghar SS, Koomen GCM, Venneker GT, Struijk DG, Arisz L: Effects of renal failure on complement C3d levels. Nephron 1991;59:41-45.
8. Zemel D, Koomen GCM, Hart AAM, ten Berge RJM, Struijk DG, Krediet RT: Relationship of TNF-α, interleukin-6 and protaglandins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 1993;122:686-696.
9. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT: The growth factors VEGF and TGF-beta in peritoneal dialysis. J Lab Clin Med 1999;134:124-132.
10. De Boer AW, Levi M, Reddingius RE, Willems HL, van den Bosch S, Schröder CH, Monnens LAH: Intraperitoneal hypercoagulation and hypofi brinolysis is present in childhood peritonitis. Pediatr Nephrol 1999;13:281-287.
11. Pannekeet MM, Zemel D, Koomen GCM, Struijk DG, Krediet RT: Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Perit Dial Int 1995;15:217-225.
12. Krediet RT: Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001;21:560-567.
13. Coester AM, Struijk DG, Smit W, de Waart DR, Krediet RT: The cellular contribution to effluent potassium and its relation with free water transport during peritoneal dialysis. Nephrol Dial Transplant 2007;22:3593-3600.
14. Pecoits-Filho R, Araujo MRT, Lindholm B, et al: Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002;17:1480-1486.
15. Rodrigues A, Martins M, Santos MJ, et al: Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor and interleukin-6. Relationship with peritoneal transport. Adv Perit Dial 2004;20:8-12.
16. Van Esch S, Zweers MM, Jansen MAM, de Waart DR, van Manen JG, Krediet RT: Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients. Perit Dial Int 2004;24:554-561.
17. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT: Longitudinal follow-up of CA-125 in peritoneal effluent. Kidney Int 1997;51:888-893.
18. Zweers MM, Struijk DG, Krediet RT: Vascular endothelial growth factor in peritoneal dialysis. J Lab Clin Med 2001;137:125-132.
19. Rodrigues AS, Martins M, Korevaar JC, et al: Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters. Am J Nephrol 2007;27:84-91.
20. Rippe B, Simonsen O, Heimburger O, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-357.
21. Jones S, Holmes CJ, Krediet RT, et al: Bicarabonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001;59:1329- 1338.
22. Williams JD, Topley N, Craig KJ, et al: The Euro-Balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-418.
23. Haas S, Schmitt P, Arbeites K, et al: Improved acidosis correction and recovery of mesothelial cell mass with neutral pH bicarabonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 2003;14:2632-2638.
24. Vlijm A, Stoker J, Bipat S, et al: CT findings characteristics for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2009;in press.